Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.3K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
Tumor Progression02:07

Tumor Progression

7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrasound priming gated by solid tumor hallmarks to guide CAR-T therapy.

Science advances·2026
Same author

Application of Label-Free Detection Using Tapered Optical Fiber System for Head and Neck Cancer and Infectious Biomolecules.

Head & neck·2026
Same author

ETS1 Orchestrates a Hybrid EMT Program Driving Metastasis and Immune Evasion.

Cancer research·2026
Same author

Tissue regenerative medicine: Clinical advances, challenges, and opportunities.

APL bioengineering·2025
Same author

A high-power spatial, single-cell view of pericytes in esophageal cancer metastasis.

Nature genetics·2025
Same author

Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell Carcinoma.

Cancer research·2025

Related Experiment Video

Updated: Jan 15, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K

Precision Epigenetic Reprogramming: CoREST Inhibition Sensitizes STK11-Mutant Tumors to Immune Checkpoint Blockade

De-Chen Lin1, Keyue Shen2

  • 1Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.

Cancer Research
|October 15, 2025
PubMed
Summary

Loss-of-function mutations in STK11 (also known as LKB1) cause resistance to immunotherapy in non-small cell lung cancer. Targeting the CoREST complex with TNG260 restores immune sensitivity and enhances anti-PD-1 therapy efficacy.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.5K
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.5K

Related Experiment Videos

Last Updated: Jan 15, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.5K
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.5K

Area of Science:

  • Oncology
  • Immunology
  • Epigenetics

Background:

  • Loss-of-function mutations in STK11 (also known as LKB1) characterize a non-small cell lung cancer subtype resistant to immune checkpoint blockade.
  • Immune evasion in STK11-mutant tumors is linked to epigenetic deregulation.
  • Impaired T-cell infiltration and suppressed antigen presentation contribute to treatment resistance.

Purpose of the Study:

  • To identify and pharmacologically target vulnerabilities in STK11-mutant non-small cell lung cancer to restore immune sensitivity.
  • To evaluate the efficacy of a novel CoREST complex inhibitor, TNG260, in preclinical models and early clinical trials.

Main Methods:

  • Identification of the CoREST complex, via histone deacetylase 1, as a therapeutic target.
  • Development and testing of TNG260, a selective small-molecule CoREST inhibitor.
  • Preclinical studies in STK11-deficient non-small cell lung cancer models and analysis of early clinical trial data (NCT05887492).

Main Results:

  • TNG260 reprograms the tumor epigenome, upregulating immune genes in STK11-deficient models.
  • TNG260 synergizes with anti-PD-1 therapy, leading to durable tumor regressions in preclinical studies.
  • Early clinical data show increased histone acetylation and CD8+ T-cell infiltration in patients treated with TNG260 and pembrolizumab.

Conclusions:

  • The CoREST complex is a druggable vulnerability in STK11-mutant non-small cell lung cancer.
  • Pharmacological inhibition of CoREST can restore immune sensitivity and enhance immunotherapy efficacy.
  • Further investigation is warranted regarding durability, tumor-type specificity, and biomarker strategies.